Latest Insider Transactions at Y M Abs Therapeutics, Inc. (YMAB)
This section provides a real-time view of insider transactions for Y M Abs Therapeutics, Inc. (YMAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Y-mAbs Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Y-mAbs Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
75,000
-15.31%
|
$375,000
$5.31 P/Share
|
|
Nov 20
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
75,000
-13.27%
|
$375,000
$5.3 P/Share
|
|
Jun 08
2023
|
Laura Hamill Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+50.0%
|
-
|
|
Jun 08
2023
|
Ashu Tyagi Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+50.0%
|
-
|
|
Jun 08
2023
|
James Healy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+7.65%
|
-
|
|
Jun 08
2023
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+50.0%
|
-
|
|
Jun 08
2023
|
Gerard Ber Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+50.0%
|
-
|
|
Jun 08
2023
|
Johan Wedell Wedellsborg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+50.0%
|
-
|
|
May 15
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
101,740
+2.32%
|
$915,660
$9.65 P/Share
|
|
May 15
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
101,740
+2.32%
|
$915,660
$9.65 P/Share
|
|
Jan 17
2023
|
Vignesh Rajah SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+50.0%
|
-
|
|
Jan 17
2023
|
Steen Lisby SVP & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+50.0%
|
-
|
|
Jan 17
2023
|
Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+50.0%
|
-
|
|
Jan 17
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
40,500
+30.92%
|
-
|
|
Jan 17
2023
|
Torben Lund Hansen SVP & CHIEF TECHNICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+50.0%
|
-
|
|
Jan 17
2023
|
Joris Wilms SVP & CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+50.0%
|
-
|
|
Jan 17
2023
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+5.72%
|
-
|
|
Nov 15
2022
|
Vignesh Rajah SVP & CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
1,195
+21.88%
|
$4,780
$4.92 P/Share
|
|
Feb 22
2022
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-2.16%
|
$28,000
$7.85 P/Share
|
|
Feb 09
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
64,276
-10.21%
|
$385,656
$6.96 P/Share
|
|
Feb 08
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
125,863
-16.67%
|
$881,041
$7.01 P/Share
|
|
Feb 07
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
91,031
-10.76%
|
$637,217
$7.59 P/Share
|
|
Feb 04
2022
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-2.12%
|
$28,000
$7.97 P/Share
|
|
Feb 04
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
101,104
-10.67%
|
$707,728
$7.7 P/Share
|
|
Feb 03
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
35,060
-3.57%
|
$245,420
$7.9 P/Share
|
|
Feb 01
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-13.79%
|
$80,000
$10.15 P/Share
|
|
Feb 01
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+12.12%
|
$16,000
$2.0 P/Share
|
|
Jan 24
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
88,055
-4.19%
|
$880,550
$10.52 P/Share
|
|
Jan 24
2022
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-2.07%
|
$36,000
$9.84 P/Share
|
|
Jan 21
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
70,318
-3.12%
|
$703,180
$10.93 P/Share
|
|
Jan 20
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
112,767
-9.0%
|
$1,240,437
$11.33 P/Share
|
|
Jan 19
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
69,414
-5.25%
|
$694,140
$10.89 P/Share
|
|
Jan 18
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
400
-0.03%
|
$4,400
$11.46 P/Share
|
|
Jan 18
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-13.79%
|
$88,000
$11.54 P/Share
|
|
Jan 18
2022
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+12.12%
|
$16,000
$2.0 P/Share
|
|
Jan 04
2022
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-2.03%
|
$68,000
$17.12 P/Share
|
|
Dec 22
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.99%
|
$64,000
$16.36 P/Share
|
|
Dec 14
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Bona fide gift
|
Indirect |
60,000
+4.16%
|
-
|
|
Dec 14
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Bona fide gift
|
Indirect |
60,000
-4.34%
|
-
|
|
Dec 07
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
10,000
-0.72%
|
$170,000
$17.58 P/Share
|
|
Dec 06
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
44,000
-1.53%
|
$704,000
$16.49 P/Share
|
|
Dec 06
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.95%
|
$64,000
$16.35 P/Share
|
|
Nov 30
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
25,170
-0.43%
|
$427,890
$17.02 P/Share
|
|
Nov 29
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
22,437
-1.51%
|
$381,429
$17.16 P/Share
|
|
Nov 23
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
50,000
-50.0%
|
$850,000
$17.06 P/Share
|
|
Nov 23
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+33.33%
|
$100,000
$2.0 P/Share
|
|
Nov 22
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.91%
|
$72,000
$18.09 P/Share
|
|
Nov 16
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.27%
|
$76,000
$19.33 P/Share
|
|
Nov 04
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.88%
|
$108,000
$27.54 P/Share
|
|
Oct 29
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.27%
|
$96,000
$24.82 P/Share
|